Tesamorelin

Peptide Name: Tesamorelin 
 
RESEARCHED AREAS AND BENEFITS
Visceral adipose tissue reduction
Growth hormone secretion stimulation
Lipid profile metabolic improvement
Cognitive function neuroprotective effects
Hepatic fat content decrease
 
Chemical Name: trans-3-Hexenoyl-[Tyr1, Ala2, Asp36, Ala38, Arg42, Lys43, Leu44]-hGRF(1-44)NH2 CAS Number: 218949-48-5 (Free base: 901758-09-6)
 
DESCRIPTION 
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), consisting of the 44-amino acid sequence of human GHRH with an added trans-3-hexenoic acid group. This modification enhances its stability and potency, making it more resistant to enzymatic cleavage compared to natural GHRH. It functions by binding to and activating GHRH receptors in the pituitary gland, thereby stimulating the pulsatile synthesis and release of endogenous growth hormone. While its most prominent researched application is the management of HIV-associated lipodystrophy, current studies extensively explore its impact on broader metabolic disorders, non-alcoholic fatty liver disease (NAFLD), and age-related cognitive decline.
 
Targeted Lipolysis: Research consistently demonstrates its unique ability to selectively reduce visceral adipose tissue (deep abdominal fat) while preserving subcutaneous fat.
Metabolic Markers: Studies indicate significant improvements in triglyceride levels and cholesterol-to-HDL ratios in subjects undergoing treatment.
Neuroprotection: Preliminary evidence suggests that by increasing IGF-1 levels, it may support neuronal health and improve executive function in older adults.
Liver Health: Clinical trials have investigated its efficacy in reducing hepatic fat fraction, showing promise for treating metabolic dysfunction-associated steatotic liver disease (MASLD).
 
KIT INCLUDES:
1x Peptide Vial
1x 10ml Sterile Water
1x Reconstitution Kit
 
REGULATORY NOTICES
SAHPRA DISCLAIMER This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA). It is not intended to diagnose, treat, cure, or prevent any disease.
RESEARCH USE ONLY
 
SCIENTIFIC STUDIES
Effects of Tesamorelin on Visceral Fat and Body Image in HIV Patients: https://academic.oup.com/jcem/article/95/9/4291/2835394
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue: https://pubmed.ncbi.nlm.nih.gov/18503437/
Tesamorelin for the treatment of excess abdominal fat in HIV-infected patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3103062/
Effect of Tesamorelin on Liver Fat and Histology in HIV-Infected Patients: https://pubmed.ncbi.nlm.nih.gov/31513353/